Vical, Inc.

Vical, Inc. develops biopharmaceutical products leveraging patented DNA delivery technologies for the prevention and treatment of severe or life-threatening diseases, particularly focusing on infectious diseases. The company employs an innovative approach where plasmid DNA is introduced to induce muscle cells to produce specific antigens, thereby stimulating a targeted immune response within the body to combat pathogens. This platform provides a flexible method for creating various therapeutic and prophylactic agents.

Founded in 1987 by Karl Hostetler, alongside former executives from Hybritech and researchers from the University of California San Diego, Vical was established on the insight that gene delivery could revolutionize vaccine and therapeutic development. This diverse pedigree brought together expertise in biotechnology and academic research, enabling the company to pioneer novel methods for direct gene transfer and expression within living systems.

Vical's products and services cater to diverse needs, including niche, biodefense, and universal vaccines, in addition to offering DNA vaccine contract manufacturing. The company collaborates with governmental and pharmaceutical partners to advance programs aimed at critical health challenges like Ebola and malaria, and commercializes in-house programs. Its long-term vision centers on fundamentally transforming the landscape of infectious disease treatment and prevention through its proprietary technology.

High-Level Overview

Vical Incorporated was a biotechnology company that discovered and developed gene-based pharmaceutical product candidates for human therapy, focusing on DNA delivery technologies to treat oncology, infectious diseases, and metabolic disorders.[1][3] It pioneered "naked DNA" technology for vaccines and gene transfer, targeting diseases like cancer, influenza, HIV, herpes, cytomegalovirus, and neurodegenerative conditions through partnerships with major pharma firms such as Merck, Pasteur Merieux Connaught, and Rhone-Poulenc Rorer.[1] The company served patients with genetic and acquired diseases by introducing therapeutic genes into cells, emphasizing ease of manufacturing and cost-effectiveness over traditional methods.[1] Vical was acquired by Brickell Biotech, Inc., in a reverse merger on August 31, 2019, marking the end of its independent operations.[4]

Origin Story

Vical was founded in June 1987 in San Diego, California, as a biotech startup targeting drugs for AIDS, herpes, and other viral diseases.[2] It secured $1 million in seed capital from Biovest Partners, with Biovest principal Timothy Wollaeger serving as chairman, followed by a $2.5 million venture round from investors including Morgenthaler Ventures, Hillman Ventures, Sutter Hill Ventures, Sequoia Capital, and Security Pacific Capital.[2] Wick Goodspeed, with prior executive roles at Baxter International and British Oxygen Healthcare, was hired as president shortly after formation.[2] The company evolved from early viral disease focus to broader gene therapy R&D, signing key collaborations like the 1991 Merck deal for infectious disease vaccines and expanding into oncology and metabolic proteins by the mid-1990s.[1] Vijay B. Samant joined as President and CEO in November 2000, bringing sales and marketing expertise.[5]

Core Differentiators

• Naked DNA Technology: Vical's proprietary gene transfer method used non-infectious plasmids for direct DNA delivery into cells, avoiding viral vectors and enabling broad applicability for vaccines and therapies without complex fermentation.[1]
• Manufacturing and Cost Advantages: Emphasized simplicity, scalability, and potential cost-effectiveness compared to conventional biotech processes, positioning it for commercialization in oncology, infectious diseases, and metabolic disorders.[1]
• Strategic Partnerships: Exclusive licenses with pharma giants like Merck (influenza, HIV, others), Pasteur Merieux Connaught (CMV, RSV, Lyme, etc.), and Rhone-Poulenc Rorer for neurological proteins, providing validation and funding.[1]
• Pipeline Focus: Internal development of cancer candidates alongside collaborative vaccines, differentiating through diverse therapeutic targets from genetic diseases to neurodegeneration.[1][3]

Role in the Broader Tech Landscape

Vical rode the early wave of gene therapy and DNA vaccine innovation in the late 1980s and 1990s, when biotech shifted toward genetic approaches for intractable diseases like AIDS, cancer, and infections amid limited traditional drug options.[1][2] Its timing capitalized on emerging DNA tech post-HIV crisis, influencing pharma's adoption of naked DNA platforms—seen in deals with Merck and others that accelerated vaccine R&D.[1] Market forces like rising infectious disease threats and oncology needs favored its model, contributing to the startup ecosystem via VC backing from Sequoia and Sutter Hill, which funneled capital into San Diego's biotech hub.[2] Vical helped pioneer non-viral gene delivery, paving the way for modern mRNA and DNA therapies, though its influence waned post-acquisition amid biotech consolidation.[4]

Quick Take & Future Outlook

Vical's legacy as a gene therapy trailblazer endures through its DNA tech influence on vaccines and oncology, but as an independent entity, it ceased with the 2019 reverse merger into Brickell Biotech, shifting focus to dermatology under new leadership.[4] Brickell may leverage Vical's delivery expertise amid rising demand for genetic medicines in immuno-oncology and pandemics. Trends like CRISPR advancements and mRNA dominance could revive similar platforms, potentially evolving Vical's IP through Brickell or licensing—watch for pipeline progress in infectious diseases as global health threats persist. This early biotech pioneer's story underscores how foundational tech seeds enduring ecosystem impact.